Evolving concepts of type 2 diabetes management with oral medications: New approaches to an old disease

Current Medical Research and Opinion

Volumn 24, Issue 8, 2008, Pages 2189-2202

  Henry, Robert R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Glucose; Oral antidiabetic agents; Type 2 diabetes mellitus

Indexed keywords

6 (3 AMINO 1 PIPERIDINYL) 1 (2 CYANOBENZYL) 3 METHYLURACIL; ACARBOSE; ANTIDIABETIC AGENT; BILE ACID SEQUESTRANT; CANNABINOID RECEPTOR ANTAGONIST; COLESEVELAM; COLESTILAN; DIGOXIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FENOFIBRATE; GASTRIC INHIBITORY POLYPEPTIDE ANTAGONIST; GLITAZONE DERIVATIVE; INSULIN; METFORMIN; METOPROLOL; MEVINOLIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; PRAVASTATIN; RIMONABANT; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TARANABANT; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; VILDAGLIPTIN; WARFARIN;

ABDOMINAL PAIN; ANXIETY DISORDER; ARTHRALGIA; BACKACHE; BODY WEIGHT; BURSITIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; COUGHING; DATA BASE; DEPRESSION; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SCREENING; DYSLIPIDEMIA; EVIDENCE BASED PRACTICE; FATIGUE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GLUCONEOGENESIS; GLYCEMIC CONTROL; GLYCOGENOLYSIS; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INFLUENZA; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIMB PAIN; LIVER TOXICITY; MEDLINE; METABOLIC REGULATION; MICROANGIOPATHY; MONOTHERAPY; MOOD DISORDER; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL EDEMA; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; RISK REDUCTION; SIDE EFFECT; SUICIDE; SWEATING; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEIGHT GAIN;

ADMINISTRATION, ORAL; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; RECEPTOR, CANNABINOID, CB1;

EID: 50149089590     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802212981     Document Type: Review

References (82)

1. Anon. Standards of medical care in diabetes - 2007. Diabetes Care 2007;30(Suppl 1):S4-S41
2. Anon. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
3. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17
4. Buse JB. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007; 99:S21-S33
5. Anon. Major international diabetes study does not confirm increased risk of death reported by US trial. Available at: http://www.advance-trial.com/static/upload/PDF/Media_release_Feb08.pdf [last accessed March 10, 2008]
6. Abraira C, Duckworth W, McCarren M, et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. J Diabetes Complications 2003; 17:314-22
7. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. J Am Med Assoc 2004-291:335-42
8. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). J Am Med Assoc 1999-281:2005-12
9. Kulkarni K. Diets do not fail: the success of medical nutrition therapy in patients with diabetes. Endocr Pract 2006;12 (Suppl 1):121-3
10. PRECOSE (acarbose tablets) prescribing information. Available at: http://www.univgraph.com/Bayer/inserts/Precose.pdf [last accessed July 26, 2007]
11. GLYSET(miglitol tablets) prescribing information. Available at: http://www.pfizer.com/files/products/uspi_glyset.pdf [last accessed July 26, 2007]
12. GLUCOPHAGE XR (metformin hydrochloride extended-release tablets) prescribing information. Available at: [http://packageinserts.bms.com/pi/ pi_glucophage_xr.pdf [last accessed November 1, 2006]
13. JANUVIA (sitagliptin tablets) prescribing information. Available at: http://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdf [last accessed July 26, 2007]
14. STARLIX (nateglinide tablets) prescribing information. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/Starlix.pdf [last accessed July 26, 2007]
15. PRANDIN (repaglinide tablets) prescribing information. Available at: http://www.prandin.com/docs/prandin-insert.pdf [last accessed July 26, 2007]
16. MICRONASE (glyburide) prescribing information. Available at: http://www.pfizer.com/files/products/uspi_micronase.pdf [last accessed November 1, 2006]
17. AMARYL (glimepiride tablets) prescribing information. Available at: http://products.sanofi-aventis.us/amaryl/amaryl.pdf [last accessed July 26, 2007]
18. GLUCOTROL XL (glipizide) extended release tablets prescribing information. Available at: http://www.pfizer.com/files/products/ uspi_glucotrol_xl.pdf [last accessed December 9, 2007]
19. AVANDIA (rosiglitazone maleate tablets) prescribing information. Available at: http://us.gsk.com/products/assets/us_avandia.pdf [last accessed July 26, 2007]
20. ACTOS (pioglitazone hydrochloride tablets) prescribing information. Available at: http://www.actos.com/actos/prescribinginfo.aspx [last accessed July 26, 2007]
21. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164:2097-104
22. IDF Clinical Guidelines Task Force. Global guideline for Type 2 diabetes. Brussels: International Diabetes Federation; 2005
23. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). [Lancet] 1998;352:854-65
24. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29:1963-72
25. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New Engl J Med 2007;356:2457-71
26. Meinert CL, Knatterud GL, Prout TE, et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970;19(Suppl):789-830
27. JANUMET (sitagliptin-metformin combination tablets) prescribing information. Available at: http://www.merck.com/proctuct/usa/ pi_circulars/j/janumet/janumet_pi.pdf [last accessed July 26, 2007]
28. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008; 10:376-86
29. DeFronzo RA, Hissa M, Blauwet MB, et al. Saxagliptin added to metformin improves glycemia control in patients with type 2 diabetes, 67th Annual American Diabetes Association Scientific Sessions, Chicago, IL, June 22-26, 2007
30. Takeda submits new drug application for alogliptin (SYR-322) in the US. Available at: http://www.takeda.com/press/article_28864.html [last accessed March 15, 2008]
31. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-7
32. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49:2564-71
33. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43
34. Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006; 28:1556-68
35. Pratley RE, Jauffret-Kamel S, Galbreath E, et al. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006;38:423-8
36. Dejager S, Razac S, Foley JE, et al. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007-39:218-23
37. Pi-Sunye FX, Schweizer A, Mills D, et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 76:132-8
38. Schweizer A, Couturier A, Foley JE, et al. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes. Diabetic Med 2007;24:955-61
39. Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007;30:217-23
40. Rosenstock J, Baron MA, Camisasca RP, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9:175-85
41. Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30:890-5
42. Ahren B, Gomis R, Standl E, et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004; 27:2874-80
43. Ahren B, Pacini G, Foley JE, et al. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005; 28:1936-40
44. Garber AJ, Schweizer A, Baron MA, et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007;9:166-74
45. Lichtman AH, Cravatt BF. Food for thought: endocannabinoid modulation of lipogenesis. J Clin Invest 2005;115:1130-3
46. Finer N, Pagotto U. The endocannabinoid system: a new therapeutic target for cardiovascular risk factor management. Br J Diabetes Vasc Dis 2005;5:121-4
47. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New Engl J Med 2005;353:2121-34
48. Iranmanesh A, Rosenstock J. Late-breaking trial: SERENADE, International Diabetes Federation 19th World Diabetes Congress, Cape Town, South Africa, December 3-7, 2006
49. New data shows Acomplia (rimonabant) benefited patients with type 2 diabetes by improving blood sugar control, reducing weight and acting on other cardiometabolic risk factors. Available at: http://en.sanofi-aventis.com/press/ppc-14733.asp [last accessed May 15, 2008]
50. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006;368:1660-72
51. Bermudez-Siva FJ, Serrano A, Diaz-Molina FJ, et al. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur J Pharmacol 2006;531:282-4
52. Cleland SJ, Sattar N. Does rimonabant pull its weight for type 2 diabetes? Lancet 2006;368:1632-4
53. Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007;370:1706-13
54. Insull Jr W. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 2006; 99:257-73
55. De Fabiani E, Mitro N, Gilardi F, et al. Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. J Biol Chem 2003;278:39124-32
56. Suzuki T, Oba K, Futami S, et al. Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia: a case-control study comparing colestimide with acarbose. J Nippon Med Sch 2006;73:277-84
57. Yamagata K, Daitoku H, Shimamoto Y, et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxol. J Biol Chem 2004;279:23158-65
58. Bandisocle MS, Boshell BR. Hypocholesterolemic activity of colestipol in diabetes. Curr Ther Res Clin Exp 1975;18:276-84
59. Duntsch G. [Colestipol by hypercholesteremia in diabetics]. Fortschr Med 1977;95:1492-6
60. Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 1994;121:416-22
61. Tonolo G, Melis MG, Formato M, et al. Additive effects of simvastatin beyond its effects on LDL-cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000; 30:980-7
62. Yamakawa T, Takano T, Utsunomiya H, et al. Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocr J 2007;54:53-8
63. Zieve FJ, Kalin MF, Schwartz SL, et al. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007;29:74-83
64. Bays H, Dujovne C. Colesevelam HCl a non-systemic lipid-altering drug. Expert Opin Pharmacother 2003;4:779-90
65. Braunlin W, Zhorov E, Smisek D. In vitro comparison of bile acid binding to colesevelarn HCl and other bile acid sequestrants. Polymer Preprints; 2000;41:708-9
66. Bailey WL, Jones MR, Abby SL. Colesevelam. HCl for the management of type 2 diabetes mellitus?: rationale for a clinical trial program, American College of Clinical Pharmacy Annual Meeting, St. Louis, MO, October 26-29, 2006
67. Bays HE, Cohen DE. Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus. Curr Med Res Opin 2007;23:1673-84
68. WELCHOL (colesevelam HCl tablets) prescribing information. Available at: http://www.welchol.com/pdf/Welchol_PI.pdf [last accessed May 15, 2008]
69. Parker JC, Irwin N, Lavery KS, et al. Metabolic effects of subchronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice. Biol Chem 2007;388:221-6
70. Irwin N, McClean PL, O'Harte F P, et al. Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro(3))GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice. Diabetologia 2007;50:1532-40
71. Shah OJ, Kimball SR, Jefferson LS. The Src-family tyrosine kinase inhibitor PP1 interferes with the activation of ribosomal protein S6 kinases. Biochem J 2002;366:57-62
72. Tremblay F, Krebs M, Dombrowski L, et al. Overactivation of S6 kinase 1 as a cause of human insulin resistance during increased amino acid availability. Diabetes 2005;54:2674-84
73. Andrews RC, Rooyackers O, Walker BR. Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 2003;88:285-91
74. Schwartz S, Rendell M, Ahmann A, et al. Metabolic effects of 14-day treatment with DIO-902: results of a randomized, placebo-controlled trial in patients with type 2 diabetes, 67th Annual American Diabetes Association Scientific Sessions, Chicago, IL, June 22-26, 2007
75. Leighton B, Atkinson A, Coghlan MP. Small molecule glucokinase activators as novel anti-diabetic agents. Biochem Soc Trans 2005-133:371-4
76. Zhang ZY, Lee SY. PTP1B inhibitors as potential therapeutics in the treatment of type 2 diabetes and obesity. Expert Opin Investig Drugs 2003;12:223-33
77. Hussey EK, Clark RV, Amin DM, et al. Early clinical studies to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of sergliflozin, a novel inhibitor or renal glucose reabsorption, in healthy volunteers and subjects with type 2 diabetes mellitus, 67th Annual American Diabetes Association Scientific Sessions, Chicago, IL, June 22-26, 2007
78. Hussey EK, Dobbins RL, Stolz RR, et al. A double-blind randomized repeat dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of three times daily dosing of sergliflozin, a novel inhibitor of renal glucose reabsorption, in healthy, overweight and obese subjects, 67th Annual American Diabetes Association Scientific Sessions, Chicago, IL, June 22-26, 2007
79. van Poelje PD, Potter SC, Chandramouli VC, et al. Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in Zucker diabetic fatty rats. Diabetes 2006;55:1747-54
80. Okuno A, Takahashi K, Tanaka J, et al. CS-917, a fructose 1,6-bisphosphate inhibitor, suppresses gluconeogenesis in human hepatocytes, whereas metformin stimulates glycolysis in Caco-2 cells, 67th Annual American Diabetes Association Scientific Sessions, Chicago, IL, June 22-26, 2007
81. Van Poelje PD, Potter SC, Haughey MP, et al. MB06322 (CS-917), but not metformin, lowers blood glucose by inhibiting gluconeogenesis in Zucker diabetic fatty rats, 67th Annual American Diabetes Association Scientific Sessions, Chicago, IL, June 22-26, 2007
82. Walker JR, Triscari J, Freudenth S, et al. Pharmacokinetics and pharmacodynamics of single-dose CS-917, a novel prodrug of a fructose 1,6-bisphosphate inhibitor, in patients with type 2 diabetes, 67th Annual American Diabetes Association Scientific Sessions, Chicago, IL, June 22-26, 2007